<SEC-DOCUMENT>0001193125-21-030605.txt : 20210406
<SEC-HEADER>0001193125-21-030605.hdr.sgml : 20210406
<ACCEPTANCE-DATETIME>20210205162559
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-21-030605
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g125453dsp1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 East Colorado Boulevard, Suite 700 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pasadena, CA 91105 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 5, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Via EDGAR (filed as Correspondence) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U. S. Securities
and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporate Finance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Life Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street N.E. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Frank Wyman and Li Xiao </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Re:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Arrowhead Pharmaceuticals, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the Fiscal Year Ended September&nbsp;30, 2020</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed November&nbsp;23, 2020</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38042</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This letter responds to the comments of the staff of the Securities and Exchange Commission&#146;s Division of Corporation Finance (the
&#147;Staff&#148;) contained in the Staff&#146;s letter addressed to Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc. (the &#147;Company&#148;), dated January&nbsp;27. 2021, regarding the above-referenced filing. For
your convenience, we have repeated the Staff&#146;s comments before the Company&#146;s responses below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#146; Results of Operations </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Operating Expenses, page 55 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>You have omitted a discussion and analysis of changes in operating expenses between FY 2019 and FY 2018. In
future filings, please provide a complete discussion and analysis of operating results for each period presented, or identify the location in the prior filing where the omitted discussion may be found in accordance with Instruction 1 to Item 303(a)
of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company acknowledges the Staff&#146;s comment, and,
in future filings, the Company will provide a complete discussion and analysis of operating results for each period presented, or identify the location in the prior filing where the omitted discussion may be found in accordance with Instruction 1 to
Item 303(a) of Regulation <FONT STYLE="white-space:nowrap">S-K.</FONT> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">February 5, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Research and Development Expenses, page 55 </U></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Please expand your presentation to include a quantification of development costs for individual research and
development projects, as presented in the pipeline chart on page 1, and an explanation of key factors underlying changes in these amounts from the earliest period presented. If you do not separately track costs by individual project, please disclose
this fact. </B></P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">We respectfully advise the Staff that we do not separately track development costs by individual
research and development projects, including by individual drug candidates. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation
expenses, depreciation and amortization expenses, and other expenses for research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Please do not hesitate to
call me at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">626-304-3419</FONT></FONT> if you have any questions or would like any additional information regarding this matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">/s/ Kenneth A.
Myszkowski, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Kenneth A. Myszkowski, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">cc</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick O&#146;Brien, General Counsel</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ryan
Murr, Gibson, Dunn&nbsp;&amp; Crutcher LLP</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Damien Pineda, Rose, Snyder&nbsp;&amp; Jacobs LLP</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g125453dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g125453dsp1.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H .U #2Q S1Y
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H !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
